Lauren Fishbein MD, PhD, MTR, is an Associate Professor of Medicine at the University of Colorado School of Medicine in the Division of Endocrinology, Metabolism and Diabetes with a secondary appointment in the Department of Biomedical Informatics, and she is the Director of the Neuroendocrine Tumor Clinical and Research Program. She received her MD, PhD from the University of Florida and completed internship and residency in Internal Medicine at Harvard Beth Israel Deaconess Medical Center in Boston. She then completed a clinical and research fellowship in Endocrinology at the University of Pennsylvania where she also earned a Master’s in Translational Research.
Dr. Fishbein has a strong interest in personalized medicine including understanding the impact of germline predisposition genetics for endocrine tumor syndromes, as well as understanding neuroendocrine tumor development and metastatic disease. Her research program investigates the interplay between somatic and germline genetics in neuroendocrine tumors, with a focus on pheochromocytoma and paraganglioma. Her research has been funded by the American Cancer Society and the National Institutes of Health.
She has held several service positions within the Endocrine Society. She was a co-chair of the Trainee and Career Development Core Committee, chaired the Early Career Forum and Career Development Workshops for several years, and was the Endocrine Society early career representative for the FASEB Training and Career Opportunities Subcommittee. She co-chaired the Adrenal and Pituitary Special Interest Group and has been a member of the Research Affairs Core Committee. She has served as Clinical Science Chair for the Annual Meeting Steering Committee for ENDO 2021 and overall Chair for ENDO 2024. She is an associate editor for Endocrine Reviews. She has been involved in other organizations as well, including Chair of the Guidelines Committee for the North American Neuroendocrine Tumor Society and serving as Executive Chair of the American-Australian-Asian-Adrenal Alliance (A5) international research consortium. She also serves on the Medical Advisory Board and Chairs the Research Advisory Board for the Pheo Para Alliance, a non-profit organization for patient education and advocacy around pheochromocytoma and paraganglioma.
